<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20037">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948011</url>
  </required_header>
  <id_info>
    <org_study_id>P13-01 / BP0.52</org_study_id>
    <secondary_id>2013-002746-36</secondary_id>
    <nct_id>NCT01948011</nct_id>
  </id_info>
  <brief_title>Racecadotril Suspension Linearity Study &amp; Comparative Bioavailability Versus Granules</brief_title>
  <official_title>Study of the Racecadotril Linearity After Single Administrations of 10, 30 and 60 mg of a New Racecadotril Formulation (Suspension) by Oral Route and Evaluation of the Comparative Bioavailability of This New Formulation Versus the Sachet Formulation (Granules) After a 60 mg Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the Racecadotril pharmacokinetic linearity after single oral administration
      of 10, 30 and 60 mg as a suspension.

      To evaluate the comparative bioavailability of the new Racecadotril formulation (suspension)
      versus the reference sachet formulation (granules)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label, single oral dose, 4-period cross-over study to assess
      the bioequivalence of a new formulation (suspension) in healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Bio-equivalence</measure>
    <time_frame>Total study duration per subject should be 6 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Several blood sample will be collected at each period to investigate the racecadotril pharmacokinetic linearity and to evaluate the comparative bioavalibility.
4-period, cross over, single oral dose at each period.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Racecadotril 10mg suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Racecadotril 30mg suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Racecadotril 60mg suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Racecadotril 60mg granules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racecadotril suspension</intervention_name>
    <description>Racecadotril suspension at 10, 30 and 60mg. Single oral dose.</description>
    <arm_group_label>Racecadotril 60mg granules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racecadotril granules</intervention_name>
    <description>Racecadotril granules at 60mg. Single oral dose.</description>
    <arm_group_label>Racecadotril 10mg suspension</arm_group_label>
    <arm_group_label>Racecadotril 30mg suspension</arm_group_label>
    <arm_group_label>Racecadotril 60mg suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male,

          -  18 to 45 years old,

          -  be certified as normal by a comprehensive clinical assessment (detailed medical
             history and a complete physical examination), arterial blood pressure (BP), heart
             rate (HR), an ECG and laboratory investigations (haematological, blood chemistry
             tests, urinalysis), the results of which are within the normal range and/ or judged
             by the investigator as clinically acceptable for healthy subjects,

          -  Body Mass Index (BMI) between 18 and 28 kg/m2.

        Exclusion Criteria:

          -  History of cardiovascular, pulmonary gastro-intestinal, hepatic, renal, metabolic,
             haematological, neurological, psychiatric, systemic, or infectious disease.

          -  Any other condition which, in the opinion of the Investigator, would jeopardize the
             safety of the subject or impact the validity of the study results.

          -  Subject has used any drug including OTC products two weeks before the scheduled
             administration of study drug, except paracetamol (maximum 1g/day).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Donazzolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EUROFINS OPTIMED</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetorphan</mesh_term>
    <mesh_term>Thiorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
